ストックスクリーナーアプリを入手
745.64
0.40%
2.29
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Has $21.56 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
(REGN) On The My Stocks Page - Stock Traders Daily
Multiple Myeloma Market on Track for Major Expansion by 2034, According to DelveInsight | Janssen Pharma, Regeneron Pharma, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron - Barchart
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Myopic Macular Degeneration Market Forecasted to Surge - openPR
Retireful LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Multiple Myeloma Market on Track for Major Expansion by 2034, - openPR
Breakthrough Therapy BT Designation Market Is Booming - openPR
Artery Stenosis Drug Market Insights Comprehensive Trends, - openPR
Retinal Biologics Market: Future Scope, Growth Potential, - openPR
Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Regeneron: The Biotech Stock To Buy Now (NASDAQ:REGN) - Seeking Alpha
Eczema Therapeutics Market 2024-2031 Revenues Will Increase - openPR
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3 - Insider Monkey
Familial Hypercholesterolemia Market Forecasted to Surge - openPR
Quest Partners LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Macular Degeneration Treatment Market Is Expected To Reach - openPR
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
10 Biggest Biotechnology Companies - Investopedia
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria - Yahoo Finance
Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP - Law360
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Benzinga
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc. - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Geographical - openPR
2 Top Growth Stocks to Buy on the Dip - AOL
Swiss National Bank Acquires 2,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Seizert Capital Partners LLC - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewswire Inc.
Mizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by CIBC Asset Management Inc - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research - MarketBeat
Rep. Greg Landsman Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat
Citigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral Recommendation - MSN
Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria - Pharmaceutical Technology
Simplify Asset Management Inc. Purchases 3,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Check Out What Whales Are Doing With REGN - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research - MarketBeat
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S. - Seeking Alpha
ING Groep NV Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA to review Sanofi, Regeneron’s Dupixent sBLA for CSU - Pharmaceutical Business Review
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup - MarketBeat
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU - MarketWatch
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous - The Bakersfield Californian
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron stock touches 52-week low at $785.31 By Investing.com - Investing.com Nigeria
Regeneron stock touches 52-week low at $785.31 - Investing.com
Citigroup Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
28 Analysts Have This To Say About Regeneron Pharmaceuticals - Benzinga
Victory Capital Management Inc. Sells 2,273 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Los Angeles Capital Management LLC Sells 773 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citi initiated coverage on Regeneron Pharmaceuticals setting a price target of $895 - Investing.com
Regeneron Pharmaceuticals' SWOT analysis: stock faces biosimilar challenge, pipeline promise - Investing.com
Parametrica Management Ltd Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease - Yahoo Finance
MQS Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Boosted by Dillon & Associates Inc. - MarketBeat
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - The Manila Times
Aigen Investment Management LP Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to Unveil Breakthrough Blood Cancer Data: 23 Studies at ASH 2024 | REGN Stock News - StockTitan
OVERSEA CHINESE BANKING Corp Ltd Has $1.39 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight - PR Newswire
0.34%
0.58%
大文字化:
|
ボリューム (24 時間):